Remibrutinib for multiple sclerosis with mri monitoring
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study tests an experimental pill called remibrutinib in people with multiple sclerosis (MS). It uses MRI scans to see how well the drug works at reducing MS activity. This could help people with relapsing or progressive MS.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 60 years old.
- You must have a confirmed diagnosis of multiple sclerosis (any type), and be able to speak English.
- You need to have signs of active disease in the last year, like a relapse or new lesions on MRI.
- You must not be currently taking other MS treatments or certain other immune system medications.
- You need to be able to undergo MRI scans with contrast.
- Your liver, kidney, and blood counts must be within safe limits, and you cannot have certain heart conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how a new pill for multiple sclerosis (MS) affects brain inflammation and immune cells. It may help people who are already taking an MS medication but want to switch to a different one.
This trial tests a daily pill called orelabrutinib to see if it can slow disability progression in people with primary progressive multiple sclerosis (PPMS). It may be an option for patients whose symptoms have been getting worse over the past two years.
This study tests ublituximab (Briumvi), a treatment given as an infusion, for people recently diagnosed with relapsing MS. The goal is to see if starting this treatment early helps control MS better.
This trial tests if ublituximab can improve walking and other motor skills in people with active relapsing MS. You must be able to walk at least 25 feet and stand 30 seconds on your own.
This trial tests an oral medication called remibrutinib to see if it can slow disability progression in people with secondary progressive multiple sclerosis (SPMS). You might join if you have had MS for a while, your symptoms have worsened over the past year, and you haven't had any recent relapses.
This study tests a new oral medication called remibrutinib for people with relapsing multiple sclerosis who are currently on Ocrevus. Participants will switch from Ocrevus to remibrutinib to see if it is safe and effective.
Hear when a new Multiple Sclerosis (MS) - Relapsing-remitting trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.